Additionally, narrative reviews have proposed plausible non-glycemic mechanisms, including inhibition of viral entry, anti-inflammatory effects, and attenuation of fibrotic pathways, through which DPP-4 inhibitors might influence the COVID-19 disease course beyond glycemic control [14]. This evidence concerns the gene DPP4 and COVID-19.